A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 577
- Sponsors Bristol-Myers Squibb
- 03 Jul 2017 Planned End Date changed from 1 Apr 2021 to 12 Oct 2024.
- 03 Jul 2017 Planned primary completion date changed from 16 Apr 2020 to 5 Sep 2020.
- 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.